Ipsen is withdrawing tazemetostat from all markets following signals of secondary hematologic malignancies observed in SYMPHONY-1 evaluating tazemetostat plus lenalidomide/rituximab versus ...

Anița was also the beneficiary of a viral social media campaign in early 2026 to raise money for her treatment, which was only available in the United States. Launched by police officer Dani Cek and ...

The University of Iowa Health Care Holden Comprehensive Cancer Center has started treating its second patient — the second in the state — with a cellular therapy to fight synovial sarcoma, a rare and ...

Ipsen initiated an immediate, worldwide withdrawal of the EZH2 inhibitor tazemetostat across follicular lymphoma and epithelioid sarcoma due to emerging safety signals. An independent data monitoring ...

Cancer drug pulled market as Ipsen removes Tazverik from the U.S. due to secondary blood cancer risks reported in clinical trials.

Rates infection related cancer have increased among solid organ transplant recipients, CDC reports a five-fold rise in Kaposi sarcoma virus transmission.

"Sometimes speaking to someone who’s in that exact, weirdly specific situation to understand how you’re feeling, I think is really helpful." ...

C-Further, an international consortium committed to creating new therapeutics for childhood cancers, today unveils the first early-stage therapeutic programmes for its pipeline, dedicated to ...

This CDC report detailed 46 cases of suspected donor-derived KSHV-related complications among 153 transplant recipients from 2021-2025, roughly five times the number of cases reported from 2016-2020.

After surviving Ewing Sarcoma, 14-year-old Jude Baker used his Make-A-Wish not for a trip, but to help people experiencing ...

Ipsen found cases of secondary malignancies in a confirmatory study of Tavzerik, a medicine it got in a purchase of Epizyme ...

After a data monitoring committee saw increased risk of secondary blood cancers in the SYPHONY-1 trial, the firm will stop selling the drug for follicular lymphoma and sarcoma.